First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

Bookmark and Share
Published: 30 May 2015
Views: 1830
Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA

Dr Usmani presents at a press conference at ASCO 2015 a phase II trial that suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma.

Read the news article and watch the interview for more.